InsiderSignal.AI

InsiderSignal.ai

LLY - Eli Lilly & Co

Insider Purchase by Ricks David A (Pres, Chair,, CEO)

1 Year
After Trade
Before Trade

Loading data...

Trade Summary

6 months ago, Ricks David A, serving as Pres, Chair,, CEO at Eli Lilly & Co (LLY), purchased 1,632 shares at $644.77 per share, for a total transaction value of $1,052,263.00. Following this transaction, Ricks David A now holds 676,970 shares of LLY.

The trade was executed on Tuesday, August 12, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, August 12, 2025, meaning the disclosure happened on the same day as the trade.

Eli Lilly & Co operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - GENERAL industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Ricks David A

Pres, Chair,, CEO

David A. Ricks (born 1967) is an American businessman serving as President, Chairman, and CEO of Eli Lilly and Company since January 2017, when he became CEO, and June 2017, when he was elected Chairman.[[1]](https://quartr.com/insights/business-philosophy/david-a-ricks-eli-lillys-chairman-and-ceo)[[2]](https://www.lilly.com/about/leadership/david-ricks)[[3]](https://en.wikipedia.org/wiki/David_A._Ricks) A Lilly veteran of nearly 30 years, Ricks joined the company in 1996 as a business development associate, progressing through roles in marketing, sales, and international operations, including general manager of Lilly Canada (2005-2008) and president of Lilly China (2008-2009), before leading Lilly USA and Lilly Bio-Medicines.[[1]](https://quartr.com/insights/business-philosophy/david-a-ricks-eli-lillys-chairman-and-ceo)[[2]](https://www.lilly.com/about/leadership/david-ricks)[[4]](https://www.healthevolution.com/bios/speaker/david-ricks/) Ricks earned a Bachelor of Science from Purdue University in 1990 and a Master of Business Administration from Indiana University in 1996, and later received an honorary doctorate in Pharmaceutical Management from Purdue.[[2]](https://www.lilly.com/about/leadership/david-ricks)[[3]](https://en.wikipedia.org/wiki/David_A._Ricks) Under his leadership, Eli Lilly has achieved record growth, particularly with GLP-1 drugs like Mounjaro (approved 2022) and Zepbound (2023), propelling the company's market cap from $70 billion to nearly $700 billion by 2025.[[1]](https://quartr.com/insights/business-philosophy/david-a-ricks-eli-lillys-chairman-and-ceo)[[5]](https://chiefexecutive.net/ceo-of-the-year-a-conversation-with-eli-lillys-dave-ricks/) He serves on boards including Adobe, Purdue University Trustees, and PhRMA (former chair).[[2]](https://www.lilly.com/about/leadership/david-ricks)[[3]](https://en.wikipedia.org/wiki/David_A._Ricks)[[7]](https://www.purdue.edu/bot/about/trustees/trustee-bios/ricks.php)

View full insider profile →

Trade Price

$644.77

Quantity

1,632

Total Value

$1,052,263.00

Shares Owned

676,970

Trade Date

Tuesday, August 12, 2025

194 days ago

SEC Filing Date

Tuesday, August 12, 2025

HEALTHCAREDRUG MANUFACTURERS - GENERAL

About Eli Lilly & Co

Company Overview

No company information available
View news mentioning LLY

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/123230

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime